{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:41:35Z","timestamp":1790757695156,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,12,3]],"date-time":"2015-12-03T00:00:00Z","timestamp":1449100800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson (US)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jonker-Driessen Foundation"},{"name":"Pharos","award":["(#80-82500-98-01007)"],"award-info":[{"award-number":["(#80-82500-98-01007)"]}]},{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development (NL)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00520-015-3032-y","type":"journal-article","created":{"date-parts":[[2015,12,3]],"date-time":"2015-12-03T06:25:24Z","timestamp":1449123924000},"page":"2411-2420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice"],"prefix":"10.1007","volume":"24","author":[{"given":"A. J. M.","family":"Beijers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Vreugdenhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Oerlemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Eurelings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Minnema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. M.","family":"Eeltink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. V.","family":"van de Poll-Franse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,3]]},"reference":[{"key":"3032_CR1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00520-013-1991-4","volume":"22","author":"K Jordan","year":"2014","unstructured":"Jordan K, Proskorovsky I, Lewis P, Ishak J, Payne K, Lordan N, et al. (2014) Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer 22:417\u2013426","journal-title":"Support Care Cancer"},{"key":"3032_CR2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","volume":"89","author":"F Mols","year":"2012","unstructured":"Mols F, Oerlemans S, Vos AH, Koster A, Verelst S, Sonneveld P, et al. (2012) Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry. Eur J Haematol 89:311\u2013319","journal-title":"Eur J Haematol"},{"key":"3032_CR3","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","volume":"11","author":"M Delforge","year":"2010","unstructured":"Delforge M, Blade J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, et al. (2010) Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 11:1086\u20131095","journal-title":"Lancet Oncol"},{"key":"3032_CR4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-014-1632-x","volume":"121","author":"JL Jongen","year":"2015","unstructured":"Jongen JL, Broijl A, Sonneveld P (2015) Chemotherapy-induced peripheral neuropathies in hematological malignancies. J Neuro-Oncol 121:229\u2013237","journal-title":"J Neuro-Oncol"},{"key":"3032_CR5","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","volume":"32","author":"DL Hershman","year":"2014","unstructured":"Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:1941\u20131967","journal-title":"J Clin Oncol"},{"key":"3032_CR6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejca.2009.12.008","volume":"46","author":"G Cavaletti","year":"2010","unstructured":"Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, et al. (2010) Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46:479\u2013494","journal-title":"Eur J Cancer"},{"key":"3032_CR7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mds329","volume":"24","author":"G Cavaletti","year":"2013","unstructured":"Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, et al. (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24:454\u2013462","journal-title":"Ann Oncol"},{"key":"3032_CR8","first-page":"300","volume":"8","author":"S Zweegman","year":"2012","unstructured":"Zweegman S, Lokhorst HM, Levin MD, Waal de E, Bos GMJ, Kersten MJ, et al. (2012) Guidelines for the treatment of multiple myeloma 2012. Ned Tijdschr Hematol 8:300\u2013320","journal-title":"Ned Tijdschr Hematol"},{"key":"3032_CR9","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","volume":"33","author":"M Maio Di","year":"2015","unstructured":"Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, et al. (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910\u2013915","journal-title":"J Clin Oncol"},{"key":"3032_CR10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1023\/A:1008344507482","volume":"9","author":"TJ Postma","year":"1998","unstructured":"Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK (1998) Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9:739\u2013744","journal-title":"Ann Oncol"},{"key":"3032_CR11","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1470-2045(06)70910-X","volume":"7","author":"E Basch","year":"2006","unstructured":"Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, et al. (2006) Patient versus clinician symptom reporting using the National Cancer Institute common terminology criteria for adverse events: results of a questionnaire-based study. Lancet Oncol 7:903\u2013909","journal-title":"Lancet Oncol"},{"key":"3032_CR12","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00520-014-2255-7","volume":"22","author":"F Mols","year":"2014","unstructured":"Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L (2014) Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer 22:2261\u20132269","journal-title":"Support Care Cancer"},{"key":"3032_CR13","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ejca.2011.04.034","volume":"47","author":"LV Poll-Franse van de","year":"2011","unstructured":"van de Poll-Franse LV, Horevoorts N, van Eenbergen M, Denollet J, Roukema JA, Aaronson NK, et al. (2011) The Patient Reported Outcomes Following Initial Treatment and Long Term Evaluation Of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 47:2188\u20132194","journal-title":"Eur J Cancer"},{"key":"3032_CR14","unstructured":"PHAROS. Population-based Haematological Registry for Observational Studies (PHAROS), http:\/\/www.pharosregistry.nl \/. Accessed 1 June 2015"},{"key":"3032_CR15","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","volume":"41","author":"TJ Postma","year":"2005","unstructured":"Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41:1135\u20131139","journal-title":"Eur J Cancer"},{"key":"3032_CR16","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1525-1438.2003.13603.x","volume":"13","author":"EA Calhoun","year":"2003","unstructured":"Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, et al. (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13:741\u2013748","journal-title":"Int J Gynecol Cancer"},{"key":"3032_CR17","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1212\/01.WNL.0000092015.03923.19","volume":"61","author":"G Cavaletti","year":"2003","unstructured":"Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, et al. (2003) Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology 61:1297\u20131300","journal-title":"Neurology"},{"key":"3032_CR18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminoncol.2005.12.010","volume":"33","author":"FH Hausheer","year":"2006","unstructured":"Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33:15\u201349","journal-title":"Semin Oncol"},{"key":"3032_CR19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1365-2141.1996.352889.x","volume":"92","author":"F Wisloff","year":"1996","unstructured":"Wisloff F, Eika S, Hippe E, Hjorth M, Holmberg E, Kaasa S, et al. (1996) Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 92:604\u2013613","journal-title":"Br J Haematol"},{"key":"3032_CR20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361\u2013370","journal-title":"Acta Psychiatr Scand"},{"key":"3032_CR21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0022-3999(02)00392-6","volume":"54","author":"HJ Michielsen","year":"2003","unstructured":"Michielsen HJ, De Vries J, Van Heck GL (2003) Psychometric qualities of a brief self-rated fatigue measure: the fatigue assessment scale. J Psychosom Res 54:345\u2013352","journal-title":"J Psychosom Res"},{"key":"3032_CR22","volume-title":"Psychometric theory","author":"JC Nunnally","year":"1978","unstructured":"Nunnally JC (1978) Psychometric theory. McGraw-Hill, New York"},{"key":"3032_CR23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","volume":"26","author":"PG Richardson","year":"2012","unstructured":"Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, et al. (2012) Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26:595\u2013608","journal-title":"Leukemia"},{"key":"3032_CR24","first-page":"411","volume":"66","author":"MA Babyak","year":"2004","unstructured":"Babyak MA (2004) What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med 66:411\u2013421","journal-title":"Psychosom Med"},{"key":"3032_CR25","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/0895-4356(90)90093-5","volume":"43","author":"B Burnand","year":"1990","unstructured":"Burnand B, Kernan WN, Feinstein AR (1990) Indexes and boundaries for \"quantitative significance\" in statistical decisions. J Clin Epidemiol 43:1273\u20131284","journal-title":"J Clin Epidemiol"},{"key":"3032_CR26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","volume":"29","author":"K Cocks","year":"2011","unstructured":"Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM (2011) Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 29:89\u201396","journal-title":"J Clin Oncol"},{"key":"3032_CR27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.2008.07378.x","volume":"143","author":"SJ Lee","year":"2008","unstructured":"Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel JF, et al. (2008) Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol 143:511\u2013519","journal-title":"Br J Haematol"},{"key":"3032_CR28","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2005.04.0824","volume":"24","author":"D Dubois","year":"2006","unstructured":"Dubois D, Dhawan R, van de Velde H, Esseltine D, Gupta S, Viala M, et al. (2006) Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol 24:976\u2013982","journal-title":"J Clin Oncol"},{"key":"3032_CR29","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpainsymman.2012.11.003","volume":"46","author":"E Boland","year":"2013","unstructured":"Boland E, Eiser C, Ezaydi Y, Greenfield DM, Ahmedzai SH, Snowden JA (2013) Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. J Pain Symptom Manag 46:671\u2013680","journal-title":"J Pain Symptom Manag"},{"key":"3032_CR30","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1007\/s11136-013-0379-8","volume":"22","author":"EM Lavoie Smith","year":"2013","unstructured":"Lavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 22:2787\u20132799","journal-title":"Qual Life Res"},{"key":"3032_CR31","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00277-014-2264-0","volume":"94","author":"MW Poel van der","year":"2015","unstructured":"van der Poel MW, Oerlemans S, Schouten HC, van de Poll-Franse LV (2015) Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry. Ann Hematol 94:651\u2013661","journal-title":"Ann Hematol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-3032-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-015-3032-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-3032-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T20:59:38Z","timestamp":1718225978000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-015-3032-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,3]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["3032"],"URL":"https:\/\/doi.org\/10.1007\/s00520-015-3032-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,3]]}}}